The Post-COVID world has an increased population suffering from
sleep issues, and good sleep is the basis to good health. An
insomnia intervention which is natural and non-invasive can be an
important aspect to achieve improved health in a post-COVID
world.
SCOTTSDALE, Ariz., Jan. 27,
2023 /PRNewswire-PRWeb/ -- Cereset® (Ce – Cerebrum
(brain) and Reset) is being used across the USA and in other countries as well as a means
to provide clients a means to help reset their own brain regulation
by passive listening to their own brain waves, which are translated
to tones by the Cereset computer technology.
"Sleep is foundational for optimal health, healing and
well-being," said principal investigator Charles H. Tegeler, M.D., chair of neurology at
Atrium Health Wake Forest Baptist, who led the team to investigate
Cereset Research in a randomized controlled clinical trial. The
effort compared patients with mild to moderate insomnia who
listened to their own brain waves for 10 sessions of approximately
an hour to those patients who were provided an active intervention
using randomized tones for the same time.
The study concluded that there was a clinically significant
insomnia improvement demonstrated over time by the Cereset Research
group. The improvements in autonomic cardiovascular regulation were
also significant for the Cereset Research group. Sleep quality,
anxiety, and depression also improved. No adverse events were
reported. The full study can be found in the SAGE Journal – Global
Advances in Integrative Medicine and Health – see:
https://doi.org/10.1177/27536130221147475.
"This study is a demonstration of our intent to help people help
themselves and achieve a natural means to health and wellbeing,"
said Lee Gerdes, Founder/CEO of
Cereset. "Though we have 50 Cereset offices now in the USA, we hope to have double and triple that
number in the near future to serve the many people we know have
health and wellbeing compromises which we can assist them to
rectify."
To learn more about Cereset see: https://cereset.com, or to find
a Cereset Client Center nearest you, see
https://cereset.com/centers. To follow Cereset see:
https://linkedin.com/company/cereset;
https://facebook.com/wearecereset;
https://instagram.com/wearecereset; or
https://twitter.com/wearecereset
Financial support for this clinical trial was supported by a
research grant from The Susanne Marcus Collins Foundation, Inc.
Sean L. Simpson was supported by
NIBIB R01EB024559 and Wake Forest Clinical and Translational
Science Institute (WF CTSI) NCATS UL1TR001420. REDCap
infrastructure for data collection and management was supported by
UL1TR001420.
Media Contact
Lee Gerdes, CEO, Cereset, 1
4802658800, info@cereset.com
Facebook
SOURCE Cereset